Drug Trial Radar · NCT05986240
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
May 8, 2024
Primary completion
Jun 2027
Study completion Mar 2030
Sponsor
- Lead sponsor
- Montefiore Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- M.D. Anderson Cancer Center; Flamingo Therapeutics NV; FDA Office of Orphan Products Development
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD
Conditions
- AML/MDS
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Interventions
DanvatirsenDrug
Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
Danvatirsen + VenetoclaxCombination product
Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3). Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response to Therapy as determined by Overall Response RateTime frame: From 21 days after initiation of study treatment to within 14 days following treatment discontinuation; up to 14 weeks total
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Montefiore Medical Center
The Bronx, New York · Recruiting
M.D. Anderson Cancer Center, Department of Leukemia
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.